Please try another search
For the nine months ended 30 September 2018, Immune Pharmaceuticals Inc revenues was not reported. Net loss applicable to common stockholders increased 65% to $24.4M. Higher net loss reflects Research and development increase of 68% to $6.2M (expense), Other income, net decrease of 94% to $15K (income), General and administrative increase of 1% to $4.7M (expense).
Period Ending: | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 |
---|---|---|---|---|
Total Revenue | 0 | 0 | 0 | 0 |
Gross Profit | ||||
Operating Income | -3.7 | -4.43 | -4.33 | -5.57 |
Net Income | -4.13 | -4.72 | -4.38 | -3.15 |
Period Ending: | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 |
---|---|---|---|---|
Total Assets | 20.72 | 22.26 | 24.33 | 28.61 |
Total Liabilities | 19.87 | 17.61 | 14.97 | 14.85 |
Total Equity | 0.84 | 4.66 | 9.36 | 13.76 |
Period Ending: | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 |
---|---|---|---|---|
Period Length: | 9 Months | 6 Months | 3 Months | 12 Months |
Cash From Operating Activities | -8.34 | -6.85 | -3.69 | -11.56 |
Cash From Investing Activities | -0.1 | -0.06 | -0.03 | 0.03 |
Cash From Financing Activities | 1.74 | 1.64 | -0.32 | 18.03 |
Net Change in Cash | -6.7 | -5.27 | -4.04 | 6.5 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review